We are live on ! Find out more
JJ

Johnson & Johnson Portfolio holdings

AUM $799M
1-Year Est. Return 253.51%
This Fund
S&P 500
This Quarter Est. Return
-5.59%
1 Year Est. Return
+253.51%
3 Year Est. Return
+280.64%
5 Year Est. Return
+320.83%
10 Year Est. Return
–
AUM
$401M
AUM Growth
-$4.01B
Cap. Flow
-$3.95B
Cap. Flow %
-985.8%
Top 10 Hldgs %
93.19%
Holding
25
New
3
Increased
–
Reduced
–
Closed
5

Top Buys

Rank Stock Value
1
RAPP
Rapport Therapeutics
RAPP
+$57.8M
2
CTNM
Contineum Therapeutics
CTNM
+$31.9M
3
RLYB icon
Rallybio
RLYB
+$6.16M

Top Sells

Rank Stock Value
1
KVUE icon
Kenvue
KVUE
+$3.91B
2
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
+$78.3M
3
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
+$54.3M
4
CLSD
Clearside Biomedical
CLSD
+$260K
5
TCON
TRACON Pharmaceuticals, Inc. Common Stock
TCON
+$36.1K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
2 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PTGX icon
1
Protagonist Therapeutics
PTGX
$9.8B
$84.9M 21.18%
2,449,183
– –
RAPP
2
Rapport Therapeutics
RAPP
$2.27B
$58.1M 14.5%
+2,498,051
New +$57.8M
CVRX icon
3
CVRx
CVRX
$78.3M
$49.2M 12.28%
4,103,430
– –
LEGN icon
4
Legend Biotech
LEGN
$3.93B
$36.1M 9%
814,586
– –
CTNM
5
Contineum Therapeutics
CTNM
$576M
$34.9M 8.7%
+1,979,173
New +$31.9M
NBTX
6
Nanobiotix
NBTX
$1.94B
$28.1M 7.02%
5,623,816
– –
MGTX icon
7
MeiraGTx Holdings
MGTX
$1.17B
$28M 6.98%
6,641,064
– –
PRCT icon
8
Procept Biorobotics
PRCT
$1.26B
$21.9M 5.46%
357,939
– –
NMRA icon
9
Neumora Therapeutics
NMRA
$321M
$18.2M 4.54%
1,849,445
– –
XNCR icon
10
Xencor
XNCR
$1.71B
$14.2M 3.53%
748,062
– –
FATE icon
11
Fate Therapeutics
FATE
$294M
$11.1M 2.77%
3,379,064
– –
ARWR icon
12
Arrowhead Research
ARWR
$12.1B
$6.44M 1.61%
247,598
– –
RLYB icon
13
Rallybio
RLYB
$90.1M
$4.87M 1.22%
+454,545
New +$6.16M
NNOX icon
14
Nano X Imaging
NNOX
$73.2M
$1.17M 0.29%
158,852
– –
VOR icon
15
Vor Biopharma
VOR
$1.38B
$1.07M 0.27%
53,733
– –
ALDX icon
16
Aldeyra Therapeutics
ALDX
$86.9M
$992K 0.25%
299,669
– –
PHGE icon
17
BiomX
PHGE
$1.67M
$646K 0.16%
10,122
– –
LAB icon
18
Standard BioTools
LAB
$294M
$552K 0.14%
311,967
– –
ACET icon
19
Adicet Bio
ACET
$77.3M
$441K 0.11%
22,780
– –
SENS icon
20
Senseonics Holdings Inc
SENS
$409M
$21.8K 0.01%
2,731
– –
CLSD
21
DELISTED
Clearside Biomedical
CLSD
– –
-11,309
Closed -$260K
KVUE icon
22
Kenvue
KVUE
$36.9B
– –
-182,329,550
Closed -$3.91B
TCON
23
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
– –
-4,200
Closed -$36.1K
FUSN
24
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
– –
-3,670,516
Closed -$78.3M
SWAV
25
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
– –
-166,812
Closed -$54.3M

Similar funds

HP
Hound Partners New York $799M AUM 9.54% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $797M AUM 4.79% 1-Year Est. Return
AGA
Arkos Global Advisors Houston, Texas $797M AUM 15.28% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
UM
Ulysses Management New York $802M AUM 5.35% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
AI
Aperture Investors New York $791M AUM 54.66% 1-Year Est. Return

Johnson & Johnson's Q2 2024 Portfolio in Review

As of Q2 2024, Johnson & Johnson held 25 positions worth $401M, down 91% from $4.41B the previous quarter. Its ten largest holdings account for 93% of the portfolio.

Johnson & Johnson withdrew a net $3.95B in Q2 2024, closing 5 positions. Its most notable exit was Kenvue, an estimated $3.91B position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 11% a quarter earlier, followed by Consumer Staples.

Against the trend, Johnson & Johnson opened a new position in Rapport Therapeutics worth $58.1M.

  • Johnson & Johnson's largest Q2 2024 buy was Rapport Therapeutics: 2,498,051 shares worth $58.1M.
  • Johnson & Johnson fully exited Kenvue in Q2 2024, selling an estimated $3.91B.
  • Johnson & Johnson's ten largest holdings make up 93% of its $401M portfolio in Q2 2024.
  • Johnson & Johnson opened 3 new positions and closed 5 in Q2 2024.
  • Johnson & Johnson's portfolio value fell 91% quarter-over-quarter to $401M.

Based on Johnson & Johnson's 13F filing for Q2 2024, filed 9 Aug 2024.